These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 17343825)

  • 1. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.
    Hashimoto K; Morishige K; Sawada K; Ogata S; Tahara M; Shimizu S; Sakata M; Tasaka K; Kimura T
    Biochem Biophys Res Commun; 2007 Apr; 356(1):72-7. PubMed ID: 17343825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro.
    Hashimoto K; Morishige K; Sawada K; Tahara M; Shimizu S; Sakata M; Tasaka K; Murata Y
    Cancer; 2005 Apr; 103(7):1529-36. PubMed ID: 15739201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geranylgeranylacetone blocks doxorubicin-induced cardiac toxicity and reduces cancer cell growth and invasion through RHO pathway inhibition.
    Sysa-Shah P; Xu Y; Guo X; Pin S; Bedja D; Bartock R; Tsao A; Hsieh A; Wolin MS; Moens A; Raman V; Orita H; Gabrielson KL
    Mol Cancer Ther; 2014 Jul; 13(7):1717-28. PubMed ID: 24737026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoprenoid geranylgeranylacetone inhibits human colon cancer cells through induction of apoptosis and cell cycle arrest.
    Yoshikawa N; Tsuno NH; Okaji Y; Kawai K; Shuno Y; Nagawa H; Oshima N; Takahashi K
    Anticancer Drugs; 2010 Oct; 21(9):850-60. PubMed ID: 20724917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
    Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
    Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
    Sawada K; Morishige K; Tahara M; Kawagishi R; Ikebuchi Y; Tasaka K; Murata Y
    Cancer Res; 2002 Nov; 62(21):6015-20. PubMed ID: 12414621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
    Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
    Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
    Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
    Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
    Montero JC; García-Alonso S; Ocaña A; Pandiella A
    Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
    Lin YJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
    Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
    Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid signals through mitogen-activated protein kinase-extracellular signal regulated kinase in ovarian theca cells expressing the LPA1/edg2-receptor: involvement of a nonclassical pathway?
    Budnik LT; Brunswig-Spickenheier B; Mukhopadhyay AK
    Mol Endocrinol; 2003 Aug; 17(8):1593-606. PubMed ID: 12730329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
    Chun J; Kim YS
    Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation.
    Wei H; Xu L; Yu M; Zhang L; Wang H; Wei X; Ruan Y
    Chembiochem; 2012 Feb; 13(3):465-75. PubMed ID: 22253097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
    Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
    Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.